Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cross-sectional study aimed to determine the prevalence of macrolide-resistant M. pneumoniae strains in a convenience series of 234 adult hospitalised and nonhospitalised subjects with a diagnosis of CAP in January 2013 to April 2015 in South Italy. Methods. Respiratory samples were subjected to real-time PCR. In M. pneumoniae-positive samples, domain V of 23S rRNA was sequenced to detect resistance-conferring point mutations. P1 major adhesion protein typing and multiple loci variable-number tandem repeat analysis (MLVA) were also performed. Results. Of the 234 samples, 15 (6.4%) were positive for M. pneumoniae. Three of these had a macrolide-re...
Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is gene...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) is an increasing problem worldwide. This study des...
SummaryThe development of macrolide resistance that occurred during 3 days of therapy with azithromy...
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cros...
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cros...
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cros...
OBJECTIVES: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections...
Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (LRTIs) for wh...
Objectives: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (L...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) is an increasing problem worldwide. This study des...
Objectives: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (L...
AbstractIn a total of 167 respiratory tract specimens from adult out-patients with confirmed Mycopla...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) infections cause upper and lower respiratory tract...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) infections cause upper and lower respiratory tract...
Mycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children, and tends ...
Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is gene...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) is an increasing problem worldwide. This study des...
SummaryThe development of macrolide resistance that occurred during 3 days of therapy with azithromy...
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cros...
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cros...
Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). This cros...
OBJECTIVES: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections...
Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (LRTIs) for wh...
Objectives: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (L...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) is an increasing problem worldwide. This study des...
Objectives: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (L...
AbstractIn a total of 167 respiratory tract specimens from adult out-patients with confirmed Mycopla...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) infections cause upper and lower respiratory tract...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) infections cause upper and lower respiratory tract...
Mycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children, and tends ...
Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is gene...
Macrolide-resistant Mycoplasma pneumoniae (MR-MP) is an increasing problem worldwide. This study des...
SummaryThe development of macrolide resistance that occurred during 3 days of therapy with azithromy...